IMAGO BIOSCIENCES INC (IMGO)
US45250K1079 - Common Stock
IMAGO BIOSCIENCES INC
NASDAQ:IMGO (1/10/2023, 7:15:28 PM)
After market: 36.01 0 (0%)36.01
+0.01 (+0.03%)
Company Profile
Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. The company is headquartered in Redwood City, California and currently employs 41 full-time employees. The company went IPO on 2021-07-16. The firm is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. The company focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The firm also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. The company tests bomedemstat in mouse models of MPNs as a single agent.
Company Info
IMAGO BIOSCIENCES INC
303 Twin Dolphin Drive, 6Th Floor
Redwood City CALIFORNIA
P: 14155295055.0
CEO: Hugh Y. Rienhoff
Employees: 41
Website: https://www.imagobio.com/
IMGO News
a year ago - InvestorPlace7 Healthcare Stocks That Will Be Big Winners in 2023Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider.
a year ago - InvestorPlace5 Top Pharma Stocks of 2022 to Buy for the Long HaulThe biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.
a year ago - Seeking AlphaMerck is best performing large U.S. pharma of 2022 (NYSE:MRK)Merck (MRK) shareholders have much to celebrate as the company is the best performing large US pharma of 2022 with a return of more than 43% this year.One of the Merck's (MRK)...
a year ago - Monteverde & Associates PCALERT: Contact The M&A Class Action Firm Regarding Its Investigation of the Merger -LBAI, IMRA, IMGO, RBA, BNFT/PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national...
a year ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, ELVT, LBC, OYST/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage...
IMGO Twits
Here you can normally see the latest stock twits on IMGO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
